Does GLP-1 use result in significant hair loss?
Experts share what you need to know about GLP-1-related hair loss as the side-effect gets more attention from researchers
TL;DR
- About 20 million people in the US, UK, and EU use GLP-1 receptor agonists for weight loss and type 2 diabetes.
- A side effect gaining attention is hair loss, reported by about 20% of survey respondents.
- The most common type of hair loss is temporary telogen effluvium, a stress-related shedding.
- A smaller percentage experience increased pattern baldness, which is genetically influenced and usually permanent.
- Hair loss can differ by hair type, with white patients reporting shedding and thinning, and Black patients reporting dryness and breakage.
- Causes of telogen effluvium include rapid weight loss, calorie restriction, and micronutrient deficiencies.
- Tirzepatide and semaglutide, especially at higher doses, are associated with higher rates of temporary hair loss.
- Women, who make up nearly 90% of telogen effluvium reports, often experience it after childbirth or weight loss surgery.
- Pattern baldness on GLP-1s may be linked to a genetic predisposition unmasked by the drug.
- Preventative strategies include adequate protein, iron, zinc, and biotin intake, though not guaranteed.
- Lower doses and slower weight loss might reduce risk.
- Temporary hair loss is reversible with nutrition and time; permanent hair loss may be treated with minoxidil or finasteride.
- Doctors advise prioritizing metabolic health over cosmetic concerns like hair loss.